Innovative antibody for

personalized medicine


Venture investment Fund “Bioprocess Capital Ventures”

is a 3,5 billion Rubles ($120 million) fund that is based in Moscow and managed by Bioprocess Capital Partners LLC. The fund was formed in December 2007 with investments from the Russian Venture Company (RVK) and Vnesheconombank (VEB).

The fund focuses on investments in innovative technologies in life sciences, biotechnology and fine chemistry sectors. Recently the Fund has invested five international biotechnology projects:

- TheraMAB LLC
- Incuron LLC
- OncoTartis LLC
- Tartis Aging LLC
- Promogen-MAB LLC